Cargando…
Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe
Objectives: Lisdexamfetamine dimesylate (LDX) is approved in some European countries for the second-line treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents when response to previous methylphenidate (MPH) treatment is considered clinically inadequate, and as a fi...
Autores principales: | Siffel, Csaba, Page, Matthew, Maxwell, Tricia, Thun, Barbara, Kolb, Nikolaus, Rosenlund, Mats, von Bredow, Dorothea, Keja, Jacco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475084/ https://www.ncbi.nlm.nih.gov/pubmed/32315539 http://dx.doi.org/10.1089/cap.2019.0173 |
Ejemplares similares
-
Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
por: Najib, Jadwiga, et al.
Publicado: (2017) -
Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2020) -
Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
por: Adler, Lenard A, et al.
Publicado: (2009) -
Efficacy and Safety of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder and Recent Methylphenidate Use
por: Jain, Rakesh, et al.
Publicado: (2013) -
Long‐term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention‐deficit/hyperactivity disorder
por: Ichikawa, Hironobu, et al.
Publicado: (2019)